Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature (5)
Blood Cancer Journal (3)
Leukemia (2)
Nature Cell Biology (1)
Nature Cancer (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (10)
Amendments and Corrections (2)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Diseases
Genetics
Pathogenesis
Stem cells

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–12 of 12 results

Advanced filters: Author: Gerard McGeehan Clear advanced filters

Erratum: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α

Marcia L. Moss
S.-L. Catherine Jin
J. David Becherer
Amendments and Corrections17 Apr 1997
Nature

Volume: 386, P: 738
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α

Marcia L. Moss
S.-L. Catherine Jin
J. David Becherer
Research20 Feb 1997
Nature

Volume: 385, P: 733-736
Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor

Gerard M. McGeehan
J. David Becherer
Judy P. Ways
Research18 Aug 1994
Nature

Volume: 370, P: 558-561
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

Warren Fiskus
Christopher P. Mill
Kapil N. Bhalla
Amendments and CorrectionsOpen Access21 May 2025
Blood Cancer Journal

Volume: 15, P: 1-2
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Revumenib, a potent and selective oral inhibitor of the menin–KMT2A interaction, is associated with a low frequency of treatment-related adverse events and promising clinical activity in patients with relapsed or refractory acute leukaemia.

Ghayas C. Issa
Ibrahim Aldoss
Eytan M. Stein
ResearchOpen Access15 Mar 2023
Nature

Volume: 615, P: 920-924
MEN1 mutations mediate clinical resistance to menin inhibition

Somatic mutations in MEN1 are identified in patients with leukaemia treated with a novel chromatin-targeting therapy, and the mechanism by which these mutations mediate therapeutic resistance is characterized.

Florian Perner
Eytan M. Stein
Sheng F. Cai
Research15 Mar 2023
Nature

Volume: 615, P: 913-919
Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes

With whole-genome screens using a bivalent MHC class I gene expression readout, Sparbier et al. identify opposing roles for Menin and KMT2A/B in modulating activating H3K4me3 versus repressive H3K27me3 at bivalent promoters to regulate gene activation.

Christina E. Sparbier
Andrea Gillespie
Mark A. Dawson
Research12 Jan 2023
Nature Cell Biology

Volume: 25, P: 258-272
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia

Armstrong and colleagues discover that combined targeting of IKAROS and MENIN is a therapeutic strategy for acute myeloid leukemia through disruption of essential leukemogenic transcriptional programs.

Brandon J. Aubrey
Jevon A. Cutler
Scott A. Armstrong
Research09 May 2022
Nature Cancer

Volume: 3, P: 595-613
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

Christopher P. Mill
Warren Fiskus
Kapil N. Bhalla
ResearchOpen Access28 Mar 2023
Leukemia

Volume: 37, P: 1336-1348
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Warren Fiskus
Steffen Boettcher
Kapil N. Bhalla
ResearchOpen Access11 Jan 2022
Blood Cancer Journal

Volume: 12, P: 1-11
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

Warren Fiskus
Christopher P. Mill
Kapil N. Bhalla
ResearchOpen Access13 Apr 2023
Blood Cancer Journal

Volume: 13, P: 1-13
Menin is necessary for long term maintenance of meningioma-1 driven leukemia

Clara Libbrecht
Hongbo M. Xie
Kathrin M. Bernt
ResearchOpen Access04 Feb 2021
Leukemia

Volume: 35, P: 1405-1417